BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Company to host conference call at 8 a.m. ET, August 27, 2025

Company to host conference call at 8 a.m. ET, August 27, 2025